SODIUM CLOXACILLIN MONOHYDRATE, one of the new semi-synthetic penicillinase-resistant penicillins, was introduced in England in 19621-3 and in the United States in 1965. When tested in vitro it has been found active against both penicillinase-producing and nonproducing staphylococci, β-hemolytic streptococci, and pneumococci. It is highly bound by serum proteins and is relatively resistant to gastric acid.
This report is an evaluation of the effectiveness of cloxacillin in group A streptococcal pharyngitis studied in two series, the first employing cloxacillin in primary treatment and the second in retreatment of streptococcal relapses following an original course of phenoxymethyl penicillin (penicillin V).
Materials and Methods.—Twenty-seven consecutive patients with acute pharyngitis associated with group A streptococci from the private practice of one of the authors (M.S.) were studied between September 1964 and January 1965. At initial visit the throats of all patients with acute pharyngitis suggestive of streptococcal origin were
STILLERMAN M, ISENBERG H, BERNSTEIN SH. Cloxacillin in Streptococcal Pharyngitis: Primary Treatment and Retreatment. Am J Dis Child. 1966;112(5):408–411. doi:10.1001/archpedi.1966.02090140080005
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: